Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Breast Cancer treatment details. Biologic therapy. Chemotherapy. Memorial Sloan-Kettering Cancer Center, New York, NY, United States

Survival: 28.9 months
Toxicity Grade: 5
Treatments: Biologic therapy
Country: United States
City/State/Province: New York, NY
Hospital: Memorial Sloan-Kettering Cancer Center
Journal: Link
Date: 1/2014

This phase 3 study involved female HER2-positive metastatic breast cancer patients who were divided into two separate treatment groups. Group A consisted of 181 patients and group B had 182 patients. No patient age information was available.

Patients in group A received chemotherapy with nonpegylated liposomal doxorubicin and paclitaxel in addition to biologic therapy with trastuzumab.

Patients in group B received chemotherapy with paclitaxel and biologic therapy with trastuzumab.

Treatment-related deaths due to unspecified causes were reported for group A. Grade 3-4 neutropenia, leucopenia, and stomatitis (inflammation of the lining of the GI tract) were also reported.

Treatment-related deaths due to unspecified causes were reported for group B. Grade 3-4 neutropenia and nerve toxicity were also reported.

The median overall survival times for groups A and B were 33.6 and 28.9 months, respectively.

This study was supported by Sopherion Therapeutics, makers of nonpegylated liposomal doxorubicin (brand name: Myocet).

Correspondence: Dr. Josť Baselga; email:

E-mail to a Friend Email Physician More Information